EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases

Brígida R Pinho, Vasco Martins, Anitta R Chacko, Célia Nogueira, Michael R Duchen, Jorge M A Oliveira

Pharmacological Reports · 2026

DOI: 10.1007/s43440-026-00829-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, 2026. Verfasst von Brígida R Pinho und 5 weiteren Autor:innen. Beteiligte Einrichtung: UCIBIO Applied Molecular Biosciences Unit, Mitochondria and Neurobiology Lab, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal. Hauptthemen laut MEDLINE: Mitophagy, Mitochondria, Mitochondrial Diseases, Mitochondrial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade do Porto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mitochondrial DNA (mtDNA) diseases are heterogeneous and lack effective treatments. Their severity correlates with mutant mtDNA load. Mitophagy degrades dysfunctional mitochondria, contributing to a healthy mitochondrial pool. USP30, a mitochondrial deubiquitinase, limits mitophagy by removing the ubiquitin tagging mitochondria for degradation. We investigated whether inhibiting USP30 could enhance mitophagy and reduce mutant mtDNA load in a heteroplasmic mitochondrial disease.

Methods

Cybrids cells harboring mutant m.8993T > G mtDNA - common cause of NARP syndrome and maternally inherited Leigh syndrome (MILS) - were treated with USP30 inhibitor MF-094 under glycolytic and oxidative phosphorylation conditions. On-target activity of MF-094 was assessed by mitochondrial ubiquitination (western-blot) and mitolysosome formation (microscopy). The mutation’s effects were investigated on cell proliferation and metabolism (respirometry and ATP levels). The impact of MF-094 on mutant mtDNA load and mtDNA copy number was quantified by PCR.

Results

Comparing with control cells (0% mutant mtDNA), cells with mutant mtDNA exhibited reduced proliferation and ATP levels under oxidative phosphorylation conditions; and reduced oxygen consumption, increased extracellular acidification, and sustained resazurin metabolism after mitochondrial inhibition under glycolytic conditions. MF-094 induced mitophagy via increased mitolysosome formation. Mechanistically, MF-094 showed on-target effects, increasing mitochondrial ubiquitination. However, chronic treatment (3–6 weeks) evoked only a small (5%) non-significant reduction in mutant mtDNA load.

Conclusions

Despite inducing mitophagy, the USP30 inhibitor MF-094 showed little potential to manage m.8993T > G related diseases, as it did not significantly reduce the load of this NARP/MILS causing mtDNA mutation. These results highlight the complexity of mutant mtDNA management and the need for innovative strategies for these disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitophagyMitochondriaMitochondrial DiseasesMitochondrial ProteinsUbiquitin ThiolesteraseHumansDNA, MitochondrialMutationOxidative PhosphorylationCell ProliferationBenzoatesFuransPyrazolesThiolester Hydrolases

Stichwörter der Autor:innen

ATP synthaseAutophagyCybridMitochondrial DNAMitochondrionUbiquitin

Substanzen

DNA, MitochondrialUsp30 protein, humanMitochondrial Proteins4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl esterUbiquitin ThiolesteraseBenzoatesFuransPyrazolesThiolester Hydrolases

Autor:innen und Institutionen

  • UCIBIO Applied Molecular Biosciences Unit, Mitochondria and Neurobiology Lab, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal.
  • Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal.
  • Department of Cell and Developmental Biology, University College London, London, UK.
  • Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Porto, Portugal.
  • UCIBIO Applied Molecular Biosciences Unit, Mitochondria and Neurobiology Lab, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal. jorgemao@ff.up.pt.
  • Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal. jorgemao@ff.up.pt.

Förderung

  • Universidade do Porto

Zitieren

APA

Pinho, B. R., Martins, V., Chacko, A. R., Nogueira, C., Duchen, M. R., & Oliveira, J. M. A. (2026). Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases. Pharmacological Reports. https://doi.org/10.1007/s43440-026-00829-7

Vancouver

Pinho BR, Martins V, Chacko AR, Nogueira C, Duchen MR, Oliveira JMA. Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases. Pharmacological Reports. 2026. doi:10.1007/s43440-026-00829-7

BibTeX
@article{Pinho2026,
  author = {Pinho, Brígida R and Martins, Vasco and Chacko, Anitta R and Nogueira, Célia and Duchen, Michael R and Oliveira, Jorge M A},
  title = {Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases},
  journal = {Pharmacological Reports},
  year = {2026},
  doi = {10.1007/s43440-026-00829-7}
}
Kostenlos starten →